Pancreatitis Trial, Recruiting NCT03568630 Sponsor: University of Nebraska Condition: Pancreatitis
Back to Pancreatitis

Pancreatitis Trial, Recruiting

NCT03568630
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 19 or older

  • People who are able to sign a written consent form agreeing to take part

  • People who are able to travel to Omaha, Nebraska in person twice a year for blood sample collection

  • People who meet the criteria for at least one of the following three groups:

    Group 1 – New or early diabetes:

    • People diagnosed with type 2 diabetes within the last 3 years (based on specific blood sugar test results or a doctor's diagnosis), OR people with high-risk pre-diabetes based on specific blood sugar or glucose test results, OR people who have been taking the medication metformin for less than 3 years for pre-diabetes

    Group 2 – Pancreatic cysts or chronic pancreas inflammation:

    • People who have a pancreatic cyst for which surgery, a specialised ultrasound, or ongoing imaging has been recommended, OR people diagnosed with long-term inflammation of the pancreas, confirmed by imaging, specialised ultrasound, functional testing, or a stomach/digestive specialist

    Group 3 – Inherited (family or genetic) risk:

    • People with two or more blood relatives (ranging from parents to first cousins) who have had pancreatic cancer, OR people with one parent, sibling, or child diagnosed with pancreatic cancer before age 60, OR people who carry a gene mutation linked to a higher-than-average risk of pancreatic cancer (such as BRCA1, BRCA2, Lynch syndrome genes, or several others — confirm full list with trial site), OR people whose personal or family history meets the criteria for a hereditary cancer syndrome that includes a relative with pancreatic cancer

Who may not be able to join:

  • People who have personally been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer)
  • People who are currently receiving active treatment for any cancer diagnosis (long-term hormonal therapy is not counted as an exclusion)
  • People who have been taking metformin for pre-diabetes for 3 years or more

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kelsey A Klute, MD, University of Nebraska

Phone: 402-559-1577

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Nebraska
Registry
ClinicalTrials.gov
Start date
26 July 2018
Est. completion
1 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of pancreas cancer cases diagnosed.; Biomarkers which may predict early pancreas cancer.; Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov